Director, 10% Owner

Director

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Institution	Shares	Value	Change
BAKER BROS. ADVISORS LP	42,896,690	$955M	UNCHANGED
BlackRock, Inc.	21,550,921	$480M	INCREASED
VANGUARD PORTFOLIO MANAGEMENT LLC	8,671,645	$193M	NEW
STATE STREET CORP	8,332,771	$185M	INCREASED
RTW INVESTMENTS, LP	7,144,524	$159M	UNCHANGED

Insider	Type	Shares	Value	Date
BAKER BROS. ADVISORS LP (Director, 10% Owner)	AWARD	32,008	$693K	2026-05-29
BAKER BROS. ADVISORS LP (Director, 10% Owner)	AWARD	18,622		2026-05-29
James M Daly (Director)	AWARD	9,311		2026-05-29
James M Daly (Director)	AWARD	16,004	$347K	2026-05-29
James M Daly (Director)	EXERCISE	8,107		2026-05-29

Acadia Pharmaceuticals Inc. (ACAD) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades